share_log

Avenue Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Fortress Biotech, Inc.(8.0%)

SEC announcement ·  Apr 17 16:11
Summary by Moomoo AI
On April 16, 2024, Fortress Biotech, Inc. filed an amendment to its Schedule 13D with the U.S. Securities and Exchange Commission, disclosing the acquisition of additional shares in Avenue Therapeutics, Inc. The filing, known as Amendment No. 4, indicates that Fortress Biotech now beneficially owns 3,564,059 shares of Avenue Therapeutics' common stock, which represents approximately 8.0% of the company's outstanding common stock. This ownership includes 250,000 shares of Class A preferred stock, convertible into 16,666 shares of common stock, and 22,222 shares issuable under warrants. The acquisition of 413,507 shares of common stock was part of an Offering Equity Grant resulting from a transaction completed in the first fiscal quarter of 2024. The filing also outlines the rights and conversion details of the Class A preferred stock and the terms of the warrants held by Fortress Biotech's executives. The Amendment No. 4 does not propose any changes to the company's management, structure, or business operations.
On April 16, 2024, Fortress Biotech, Inc. filed an amendment to its Schedule 13D with the U.S. Securities and Exchange Commission, disclosing the acquisition of additional shares in Avenue Therapeutics, Inc. The filing, known as Amendment No. 4, indicates that Fortress Biotech now beneficially owns 3,564,059 shares of Avenue Therapeutics' common stock, which represents approximately 8.0% of the company's outstanding common stock. This ownership includes 250,000 shares of Class A preferred stock, convertible into 16,666 shares of common stock, and 22,222 shares issuable under warrants. The acquisition of 413,507 shares of common stock was part of an Offering Equity Grant resulting from a transaction completed in the first fiscal quarter of 2024. The filing also outlines the rights and conversion details of the Class A preferred stock and the terms of the warrants held by Fortress Biotech's executives. The Amendment No. 4 does not propose any changes to the company's management, structure, or business operations.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more